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Abstract
Introduction
At the individual level, there is clear evidence that Human Immunodeficiency Virus (HIV)
transmission can be substantially reduced by lowering viral load. However there are few
data describing population-level HIV viremia especially in high-burden settings with sub-
stantial under-diagnosis of HIV infection. The 2nd Kenya AIDS Indicator Survey (KAIS 2012)
provided a unique opportunity to evaluate the impact of antiretroviral therapy (ART) cover-
age on viremia and to examine the risks for failure to suppress viral replication. We report
population-level HIV viral load suppression using data from KAIS 2012.
Methods
Between October 2012 to February 2013, KAIS 2012 surveyed household members,
administered questionnaires and drew serum samples to test for HIV and, for those found to
be infected with HIV, plasma viral load (PVL) was measured. Our principal outcome was
unsuppressed HIV viremia, defined as a PVL 550 copies/mL. The exposure variables
included current treatment with ART, prior history of an HIV diagnosis, and engagement in
HIV care. All point estimates were adjusted to account for the KAIS 2012 cluster sampling
design and survey non-response.
Results
Overall, 612% (95% CI: 564–661) of HIV-infected Kenyans aged 15–64 years had not
achieved virological suppression. The base10 median (interquartile range [IQR]) and mean
(95% CI) VL was 4,633 copies/mL (0–51,596) and 81,750 copies/mL (59,366–104,134),
respectively. Among 266 persons taking ART, 26.1% (95% CI: 20.0–32.1) had detectable
viremia. Non-ART use, younger age, and lack of awareness of HIV status were indepen-
dently associated with significantly higher odds of detectable viral load. In multivariate anal-
ysis for the sub-sample of patients on ART, detectable viremia was independently
associated with younger age and sub-optimal adherence to ART.
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Discussion
This report adds to the limited data of nationally-representative surveys to report population-
level virological suppression. We established heterogeneity across the ten administrative
and HIV programmatic regions on levels of detectable viral load. Timely initiation of ART
and retention in care are crucial for the elimination of transmission of HIV through sex, nee-
dle and syringe use or from mother to child. Further refinement of geospatial mapping of
populations with highest risk of transmission is necessary.
Introduction
The relationship between viremia and Human Immunodeficiency Virus (HIV) transmission at
the individual level is well established [1–3]. Furthermore, observational and clinical trial data
indicate that viral load (VL) suppression using antiretroviral therapy (ART) significantly
reduces HIV transmission through sex and breastfeeding [3, 4]. Consequently, population-
level viral load suppression is now a global public health imperative.
Metrics to describe aggregate viral load include community viral load (CVL) and population
viral load (PVL). These metrics could be described either as means (mean VL) or medians
(median VL). CVL as a summary measure of those HIV-infected persons already engaged in
HIV care is limited by the lack of comparability of populations that may have the same level of
CVL but whose underlying HIV transmission risk is modified by disparate HIV prevalence.
Additionally, the VL of those unaware of their HIV infection needs to be taken into account for
CVL to measure risk of population-level HIV transmission accurately [5]. However, PVL, the
proportion of HIV-infected persons with detectable or, conversely, undetectable VL is increas-
ingly considered as an appropriate measure for treatment and prevention programs and for
evaluating ART outcomes at the population level, as it addresses the limitations of CVL [6, 7].
In sub-Saharan Africa VL measurements are largely limited to diagnosing and monitoring
treatment failure, and their use for surveillance of population-level infectivity is uncommon.
Furthermore, previous studies have been limited to people on ART as well as national HIV and
lab surveillance registries [8–12].
Kenya has a generalized HIV epidemic and a high burden of disease. In 2012, an estimated
14 million adults were living with HIV/AIDS, of whom an estimated 90,000 were newly
infected that year [13]. Kenya is among high HIV-burden countries that have made commit-
ments to achieve 90% viral suppression among people on ART and tracking the implementa-
tion of this policy goal is vital. The 2nd Kenya AIDS Indicator Survey (KAIS 2012) provided a
unique opportunity to evaluate the impact of ART coverage on viremia and to examine the
risks for failure to suppress viral replication. This study examined population-level HIV viral
load suppression using data from this nationally representative survey.
Methods
Study design
KAIS 2012 was a nationally representative, cross-sectional survey of household residents in
Kenya. The details of the study have been described elsewhere [14]. Briefly, KAIS 2012 sur-
veyed household members, administered questionnaires, and drew serum samples to test for
HIV. For those found to be HIV-infected, PVL was measured.
Detectable HIV Viremia in Kenya
PLOS ONE | DOI:10.1371/journal.pone.0154318 May 18, 2016 2 / 14
PS001814] through the U.S. Centers for Disease
Control and Prevention (CDC), Division of Global
HIV/AIDS (DGHA). This work was also funded in part
by support from the Global Fund, World Bank, and
the Joint United Nations Team for HIV/AIDS. KAIS
2012 was supported by National AIDS and STI
Control Programme (NASCOP), Kenya National
Bureau of Statistics, (KNBS), National Public Health
Laboratory Services (NPHLS), National AIDS Control
Council (NACC), National Council for Population and
Development (NCPD), Kenya Medical Research
Institute (KEMRI), U.S. Centers for Disease Control
and Prevention (CDC/Kenya, CDC/Atlanta), United
States Agency for International Development (USAID/
Kenya), University of California, San Francisco
(UCSF), the United States Agency for International
Development (USAID/Kenya), Joint United Nations
Team on HIV/AIDS, Japan International Cooperation
Agency (JICA), the Elizabeth Glaser Pediatric AIDS
Foundation (EGPAF), Liverpool Voluntary
Counselling and Testing (LVCT), the African Medical
and Research Foundation (AMREF), the World Bank,
and the Global Fund for AIDS, TB and Malaria.
Competing Interests: The authors have declared
that no competing interests exist.
Eligible individuals were enrolled between October 2012 and February 2013. This paper
examines a sub-sample of Kenyans aged 15–64 years who had laboratory-confirmed HIV
infection.
Data collection
The interview captured demographic data, prior HIV testing and ART history. Co-morbidity
with tuberculosis (TB) was measured by self-reported lifetime history of a TB diagnosis by a
doctor or health professional. Participants who reported having been sexually active in the year
before the interview were asked for the number of sex partners in the past 12 months. In addi-
tion, the survey asked for partner-specific sexual behaviors for all reported sex partners in the
past 12 months, including condom use. Consistent condom use was defined as if the partici-
pant reported “a condom used all the time” with every partner during sexual intercourse. Sexu-
ally active respondents were also asked if they had ever exchanged money, gifts, or favors
(either received or given) for sex. Discordant partner status was obtained for partners who
resided in the same household and who consented to both the KAIS survey and HIV serologic
testing.
We also captured the geospatial location of households to enable us determine the distribu-
tion of HIV infection and HIV viremia across counties and ten programmatic regions in
Kenya.
Laboratory measurements
We screened blood specimens for HIV antibody using the Vironostika HIV-1/2 UNIF II Plus
O Enzyme Linked Immunoassay (bioMérieux, Marcy l’Etoile, France), a fourth-generation
assay. Non-reactive specimens were reported as HIV-negative. Reactive specimens were con-
firmed with the Murex HIV12OHIV Enzyme Immunoassay (DiaSorin, SpA, Saluggia, Italy),
also a fourth generation assay. Those that were reactive on both assays were reported as having
final HIV-positive results. Samples with discordant HIV results were re-tested using the same
algorithm and, if discordance persisted, the samples were tested for the presence of HIV anti-
gen using the Roche v15 polymerase chain reaction (COBASOBAS AMPLICOR HIV-1 Moni-
tor Test, version 15, Roche Molecular Diagnostics, Pleasanton, California, United States (US)).
We tested all final HIV-positive specimens for HIV-1 RNA concentration using the Abbott
M2000 Real-Time HIV-1 Assay (Abbott Laboratories, Abbott Park, Illinois, US). Each HIV-
positive specimen contributed one VL count. Specimens with PVL<550 copies/mL, the mini-
mum concentration detectable on the assay, were classified as virologically suppressed. Quality
control for PVL was conducted on ten percent of samples of HIV-infected patients at the Cen-
ters for Disease Control and Prevention (CDC) laboratory in Kisumu, Kenya. HIV-positive
specimens were tested for the presence of antiretroviral therapy (ART) using High Perfor-
mance Liquid Chromatography coupled to TandemMass Spectrometry. CD4+ T-cell count
measurements were done using the BD FACSCalibur™ flow cytometer (Becton Dickinson Bio-
Sciences, San Jose, California, US). However, 1254 specimens hemolysed during transit from
the field to the laboratory and1135 participants provided a dried blood spot only from which
we could not measure CD4+ T-cell counts. Therefore, 540% of HIV-reactive specimens could
not be subjected to CD4+ T-cell count testing at the National HIV Reference Laboratory.
Data analysis
In this paper, we examine the predictors of HIV viremia in Kenyans aged 15–64 years. Our
principal outcome variable was unsuppressed HIV viremia, defined as a PVL550 copies/mL.
Self-reported awareness of HIV status, current HIV care attendance, and current ART use was
Detectable HIV Viremia in Kenya
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augmented to include results of ART presence in the samples. Therefore, as an example, if a
respondent had ART detected in the blood, they were classified as “currently taking ART”
regardless whether they self-reported ART use or not. Furthermore, we assumed that if ART
was detected, participants were aware of their HIV infection and were in HIV care. All esti-
mates were adjusted to account for the KAIS 2012 cluster-sampling design and survey non-
response using the SURVEYFREQ procedure in SAS version 93 (SAS Institute Inc., Cary,
North Carolina, US). Appropriate domains were used for all analyses. In bivariate analysis,
population proportions and 95% confidence intervals (CI) were reported for categorical vari-
ables. We examined the overall prevalence of unsuppressed HIV viremia at PVL550 copies/
mL. We also investigated the association between unsuppressed HIV viremia and selected
socio-demographic, behavioral, and clinical characteristics for those reporting current ART use
and those not on ART. Variables found to be significant at a p-value<01 in bivariate analysis
were entered in a multivariable logistic regression model using the SURVEYLOGISTIC proce-
dure in SAS to determine characteristics that were independently associated with HIV viremia.
Variables were removed using a backward elimination process. Variables retained in the final
model at a p-value of<05 were considered significant predicators and reported.
The weighted mean and median VL estimates with corresponding 95% CI and interquartile
range (IQR) was calculated using the SURVEYMEAN procedure in SAS. The value used for
infected persons with a VL below the lowest detectable limit of<550 copies/mL was zero.
Geospatial analysis
We also determined the distribution of PVL across ten administrative and HIV programmatic
regions in Kenya and calculated the ratio of those who were virally suppressed compared to
those who were not. The ratio was calculated by dividing the weighted proportion of viremic
adults by the proportion of adults who were virally suppressed. We interpreted a value of>1 as
an indication that the population size of viremic adults was greater than adults virally sup-
pressed. Conversely, we interpreted a value<1 as indicating that the population size of viremic
adults was smaller than those who are virally suppressed.
Ethical considerations
We obtained verbal informed consent from the study participants. Participants aged 15–17
provided verbal assent after obtaining verbal consent from their parents or guardians. Verbal
consent is a standard practice for household surveys in Kenya and was preferred to ensure
completeness and quality of the informed consent process. The study interviewers signed the
consent forms as an attestation of informed participant consent. The Kenya Medical Research
Institute Ethical Review Committee, the US CDC Institutional Review Board, and the Commit-
tee on Human Research of the University of California, San Francisco reviewed and approved
the KAIS 2012 protocol and the consent procedures.
Results
Predictors of detectable viremia
Of the 648 HIV-infected persons, VL data were available for 617 (958%). Overall, the percent
of infected Kenyans aged 15–64 years with detectable VL was 612% (95% CI: 564–661)
(Table 1). The base10 median (IQR) and mean (95% CI) VL was 4,633 (0–51,596) and 81,750
(59,366–104,134) copies/mL, respectively. There were no significant differences found in the
percentage of persons with detectable viremia by sex, marital status, widowhood, educational
level, residence, region, and wealth index. However, persons aged 15–29 years had a
Detectable HIV Viremia in Kenya
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Table 1. Characteristics of HIV-infected persons and estimates of detectable viral load, Kenya AIDS Indicator Survey, 2012.
Variable Numberdetectable VL1/Total Weighted % (95% CI2) p-value
Overall
Detectable viral load1 382/617 612 (564–661)
Sex 0308
Men 121/183 643 (557–728)
Women 261/434 594 (542–645)
Age-group (years) <00001
15–29 139/175 794 (724–865)
30–64 243/442 539 (484–595)
Marital status 0932
Unmarried/not cohabitating 153/248 610 (538–681)
Married/cohabitating 229/369 614 (555–672)
Ever widowed 0136
No 290/454 631 (573–689)
Yes 92/163 557 (475–638)
Educational level 0120
No or incomplete primary 49/84 593 (473–714)
Completed primary 148/212 675 (592–757)
Secondary + 185/321 577 (514–639)
Residence 0391
Rural 225/353 630 (561–700)
Urban 157/264 589 (523–654)
NASCOP region 0158
Nairobi 37/63 562 (422–701)
Central 26/57 500 (347–653)
Coast 43/63 686 (534–838)
Eastern 35/73 452 (297–608)
Nyanza 151/227 660 (594–727)
Rift Valley 52/77 631 (473–790)
Western 38/57 660 (520–800)
Wealth index 0349
Lowest 65/96 662 (532–792)
Second 90/146 601 (491–710)
Middle 80/129 625 (535–714)
Fourth 97/151 657 (564–749)
Highest 50/95 506 (377–636)
Aware of HIV infection3 <00001
No 238/263 912 (874–949)
Yes 144/354 395 (335–455)
TB co-infection <00001
No 357/544 655 (603–706)
Yes 25/73 298 (200–401)
Currently in HIV care4 <00001
No 263/293 904 (865–943)
Yes 119/324 351 (289–413)
Currently taking ART5 <00001
No 309/351 888 (850–926)
Yes 73/266 261 (200–321)
(Continued)
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significantly higher percentage of detectable viremia at 794% (95% CI: 724–865) than per-
sons aged 30–64 years at 539% (95% CI: 484–595) (p<00001). In addition, persons who
were unaware of their infection had significantly higher levels of detectable VL (912% [95%
CI: 874–949]) compared to those who knew of their infection (395% [95% CI: 335–455])
(p<00001). Also, those who reported they were diagnosed with TB were significantly less
likely to have detectable VL (298% [95% CI: 200–401]) compared with those without a TB
diagnosis (655% [95% CI: 603–706]). Those that were enrolled in HIV care were significantly
less likely to have detectable virus compared to those not in care (351% [95% CI: 289–413]
versus 904% [95% CI: 865–943]) (p<00001). Among 266 persons currently taking ART,
261% (95% CI: 200–321) had detectable viremia compared to 888% (95% CI: 850–926)
(p<0.0001) among 351 persons not taking ART. The percentage of persons with detectable
Table 1. (Continued)
Variable Numberdetectable VL1/Total Weighted % (95% CI2) p-value
Time in care <00001
Not in care 263/293 904 (865–943)
<12 months 22/42 486 (339–633)
12–23 months 20/37 533 (348–719)
24+ months 56/174 315 (230–400)
Unknown 21/71 279 (170–389)
Sexually active in past 12 months 0208
No 97/168 564 (474–654)
Yes 285/449 628 (573–683)
HIV status of sex partner 0257
HIV-infected 77/117 598 (481–715)
HIV-uninfected 47/85 570 (465–674)
Partner not tested 161/247 666 (599–733)
Not sexually active 97/168 564 (474–654)
Number of sex partners in past 12months 0444
No partners 97/168 564 (474–654)
One partner 249/387 630 (570–691)
2+ partners 36/62 618 (489–746)
Condom use at last sex6 (N = 449) <00001
Yes 83/170 471 (396–547)
No 202/279 731 (666–796)
Consistent condom use with all partners in past 12 months6(N = 449) <00001
Yes 57/122 448 (358–538)
No 228/327 698 (638–759)
Ever exchanged sex for money/gifts (N = 449) 0220
No 252/387 640 (581–699)
Yes 33/62 560 (438–6.3)
NASCOP, National AIDS Control Programme. These regions correspond to former provinces of Kenya before the 2013 decentralization into counties.
1. Detectable viral load defined as HIV RNA concentration 550 copies/mL.
2. Confidence Interval.
3. Self-reported HIV-infected with presence of ART in blood.
4. Includes those with detectable ART in blood.
5. Either by self-report or by presence of ART in blood.
6. Among sexually active in past 12 months.
doi:10.1371/journal.pone.0154318.t001
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viremia did not differ by recent sexually activity or by the number of sex partners in the past 12
months. However, among sexually-active HIV-infected persons, the percentage with detectable
virus was lower for those who used a condom at the most recent sexual intercourse and who
consistently used condoms with all sexual partners (p<00001) (Table 1).
In bivariate analysis, younger age-group, lack of awareness of infection, no TB co-infection,
not currently in HIV care, no current ART use, time in HIV care, lack of condom use at last
sexual intercourse, and inconsistent condom use were significant predictors of detectable viral
load at a p-value<01 and were included in multivariable analysis. In multivariate analysis,
non-ART use, younger age, and lack of awareness of HIV infection were associated with signif-
icantly higher odds of detectable VL (data not shown). Persons who were not currently taking
ART had almost 12 times as high adjusted odds ratio (aOR) of having detectable VL as those
who were currently taking ART (aOR 118, [95% CI:63–222]). Compared to persons aged
30–64 years, infected persons aged 15–29 years had more than three times the adjusted odds
(aOR 33, [95% CI:21–53]), and persons unaware of their infection had more than twice the
adjusted odds of having detectable VL (aOR 22, [95% CI: 11–44]).
Among 266 persons who were currently taking ART, we observed significant differences in
the proportion of detectable viremia across age groups: 223% among persons aged 30–64 years
compared with 465% among persons aged 15–29 years (p<00001). However, a higher pro-
portion of persons who reported missing an antiretroviral dose in the past 30 days (461%) had
detectable virus compared to persons who had not missed a dose during the same time frame
(234%) (Table 2). We did not find any differences in the proportion of persons with detectable
viremia by time in HIV care or self-reported TB co-infection. Men and women who were tak-
ing ART had similar proportions of detectable viremia at 241% vs. 272%, respectively
(p = 0630) (Table 2).
In multivariate analysis for ART-experienced Kenyans, detectable viremia was indepen-
dently associated with younger age and lack of adherence to ART. Young persons aged 15–29
years taking ART had three times the adjusted odds as persons aged 30–64 years to have detect-
able viremia (aOR 31, [95% CI:14–69]) (p<0006) (Table 2). There were no other discernible
differences across socio-economic or behavioural characteristics. However, sub-optimal adher-
ence as measured by any missed ART doses in preceding 30 days tripled the adjusted odds of
having a detectable VL (aOR26, [95% CI: 10–71]) (p = 0049) compared to persons who
reported they did not miss any doses in the preceding 30 days (Table 2).
Geospatial analysis
Across all eight NASCOP regions, we estimated the proportion of HIV-infected persons who
had detectable virus as a ratio of those who did not have detectable virus (Fig 1). Nationally
there were 60% more HIV-infected people with detectable virus compared to those with
PVL<550 copies/mL. We observed some heterogeneity of this ratio across the ten surveyed
programmatic regions (varying from 08 in Eastern North to 2.7 in Rift Valley North)
(Table 3). In Nyanza, the region with the highest burden of HIV in Kenya, there were half as
many HIV-infected persons who were virologically suppressed compared to those who were
not. Overall, Rift Valley, Western, Nyanza and Coast regions had ratios higher than the
national average; whereas Nairobi, Central, and Eastern had ratios lower than the national
average.
Among those with detectable viremia, 374% knew their HIV-positive status, half (499%)
of whom had not initiated ART. Although the sample size was small (N = 31), 593% (95% CI
38-4-80.1) of ART-naïve participants with detectable viral load had CD4+ T-cell count mea-
surements>500 cells/μL indicating they were ineligible for ART under the current Kenya
Detectable HIV Viremia in Kenya
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Table 2. Predictors of detectable viral load1 among adults who are currently taking ART, Kenya AIDS Indicator Survey, 2012.
Variable Number/
Total
Weighted %
(95% CI2)
OR3
(95% CI2)
p-value Adjusted OR3,4 (95%
CI)
p-value
Overall 73/266 261 (200–321) —
Sex 0630
Female 53/194 272 (197–347) 12 (06–23)
Male 20/72 241 (140–342) Ref
Age category (Years) 0005
15–29 20/43 465 (294–636) 30 (14–66) 31 (14–69) 0006
30–64 53/223 223 (294–636) Ref Ref
Residence 0458
Rural 42/145 282 (196–367) 13 (07–24)
Urban 31/121 236 (150–321) Ref
Marital status 0377
Unmarried/not cohabitating 32/108 295 (190–399) 13 (07–25)
Married/cohabitating 41/158 240 (170–310) Ref
Ever widowed 0795
No 49/178 255 (186–325) 09 (05–18)
Yes 24/88 273 (156–390) Ref
Education 0238
No primary 6/39 163 (14–312) Ref
Complete primary 29/80 331 (216–445) 25 (07–89)
Secondary + 38/147 243 (167–319) 16 (05–53)
Wealth index 0379
Lowest 12/41 295 (115–474) 23 (06–83)
Second 15/62 208 (95–321) 14 (04–47)
Middle 15/53 290 (185–394) 22 (07–66)
Fourth 23/69 345 (197–493) 29 (08–99)
Highest 8/41 156 (27–284) Ref
Missed doses 0086
Yes 12/29 461 (257–665) 28 (11–72) 26 (10–71) 0049
Unknown 19/67 243 (138–348) 10 (05–21) 09 (04–19) 0694
No 42/170 234 (157–312) Ref Ref
Time in care 0825
<24 months 12/45 226 (111–340) 08 (04–18)
24+ months 41/151 269 (183–354) 10 (05–20)
Unknown 20/70 266 (157–375) Ref
TB co-infection 0561
No 56/202 270 (197–343) Ref
Yes 17/64 232 (127–337) 08 (04–16)
Number of sex partners in past 12 months 0833
None 21/83 243 (141–344) Ref
1 45/154 275 (197–352) 12 (06–22)
2+ 7/29 232 (61–403) 09 (03–28)
Condom use at last sex 0520
Yes 27/105 235 (155–315) Ref
No 25/78 317 (195–440) 15 (07–32)
Not sexually active 21/83 243 (141–344) 10 (06–20)
(Continued)
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guidelines. Even then, among ART-experienced persons, 622% had CD4+ T-cell counts =
<350 cells/ μL.
Discussion
To the best of our knowledge, this is the first national survey to report population-level virolog-
ical suppression in Kenya. We found high levels of viremia among HIV-infected Kenyans who
were not currently taking ART. Furthermore, we demonstrated geospatial differences in the
distribution of viremia. Our report adds to the limited data on population viral load [15, 16].
Our data compare well with previous reports of virologic suppression. In our study 388%
of all HIV-infected persons and 739% of ART-experienced persons had suppressed viremia.
In Swaziland, viral suppression was 35% and 85% among all HIV-infected persons and among
those on ART respectively, similar to results from a sub-national household survey in Kenya
that reported that 39.7% of HIV-infected adults had less than 1000 copies/ml, with 83.6% of
those on ART being virologically suppressed [15, 16]. In the US, it is estimated that between
19%-29% of people living with HIV/AIDS are optimally suppressed [17, 18]. The differences in
these estimates result from disparate methodologies for measuring VL including VL cut-offs
and underlying differences in ART access and knowledge of HIV status. In the US, it is esti-
mated that in 2010, 16% of persons with HIV infection were unaware of their HIV status, com-
pared to 42% of those in Kenya in 2012. Still, our data validate findings that treatment
outcomes in low-income countries including adherence to ART and virologic suppression are
commensurate to those in high-income countries [19, 20]. However, substantial efforts are
needed to reach the Joint United Nations Programme on HIV and AIDS (UNAIDS) 90-90-90
treatment targets and achieve 90% viral suppression among people living with HIV on ART by
the end of 2020 [21]. In this study we demonstrate that the majority of ART-naïve patients
who are aware of the HIV-positive status have CD4+ T-cell counts>500 cells/ μLand are
therefore not eligible for ART as per current Kenya national guidelines. To meet the UNAIDS
goals, expansion of eligibility criteria for ART would potentially achieve wider population-level
viral suppression.
In our study, we confirm that lack of knowledge of HIV-positive status, not being on ART
and sub-optimal adherence is an important determinant of detectable viremia, similar to find-
ings reported in other settings [11, 15]. Among persons on ART, virological failure has been
associated with concurrent TB infection [22], and recent incarceration [23]. In our study we
did not detect any difference in viral suppression among TB patients on ART. This could be
due to the fact that TB diagnosis is a vital criterion for initiation of ART in Kenya.
Table 2. (Continued)
Variable Number/
Total
Weighted %
(95% CI2)
OR3
(95% CI2)
p-value Adjusted OR3,4 (95%
CI)
p-value
Consistent condom use with all partners in past 12
months
0889
Yes 23/80 258 (167–350) Ref
No 29/103 276 (183–370) 11 (06–21)
Not sexually active 21/83 243 (141–344) 0.9 (05–17)
1Detectable viral load defined as HIV RNA concentration 550 copies/mL.
2Confidence Interval.
3Odds Ratio.
4Multivariate model adjusted for variables that were significant at <01 in the bivariate model: Age-group and missed doses.
doi:10.1371/journal.pone.0154318.t002
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Fig 1. Distribution of detectable viral load1 by NASCOP region, Kenya AIDS Indicator Survey, 2012. NASCOP, National
AIDS Control Programme. These regions correspond to former provinces of Kenya before the 2013 decentralization
into counties.Detectable viral load defined as HIV RNA concentration 550 copies/mL.
doi:10.1371/journal.pone.0154318.g001
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It is also evident that lack of knowledge of status is a strong barrier for accessing ART [24].
Without HIV testing, timely initiation of ART and retention in care, the goal of elimination of
sexual transmission as a global public health imperative will be difficult to realize [25, 26].
Additionally to achieve population-level viral suppression, cheaper and more potent ART,
increased laboratory capacity, and significant investments in health systems are required. In
particular, VL measurements are cost-effective for routine use in clinical settings to monitor
ART success [27, 28], and are increasingly proposed as a standard of care for initiation of ART
[29] and as a HIV prevention outcome [25]. Widespread availability of high quality point-of-
care VL testing is therefore warranted.
In our study we demonstrated that there is heterogeneity in viremia across geographical
regions. As HIV evolves from a generalized to a concentrated epidemic, a geospatial approach
to surveillance and implementation of HIV programs provides important insights into sub-
national variations of the HIV epidemic. This would enable identification of drivers of the epi-
demic to inform geographic prioritization and resource allocation [30]. Geospatial analysis is
consistent with UNAIDS goal of maximizing the efficiency and impact of national HIV preven-
tion programs by focusing on locations and populations with the highest HIV burden espe-
cially in resource-limited settings [31].
Our paper has several limitations. We used a PVL cut-off of 550 copies/mL as the limit of
detection yet the World Health Organization defines suppression as RNA concentrations
<1000 copies/mL for routine monitoring; other publications have used<400 copies/mL or
even lower thresholds as the technology to detect low levels of viremia has improved [32].
These differences limit our ability to compare rates of virologic suppression across different set-
tings. It would be helpful to standardize VL metrics and VL assays for global comparability of
estimates. Although we reported median and mean VL, the median VL has minimal utility in
jurisdictions that have successfully scaled-up ART and the mean VL is prone to influence of
outlying measurements. Both of these are not appropriate to quantify population-level infectiv-
ity. Due to a small sample size, we did not have sufficient power to detect differences in
Table 3. Distribution of detectable and non-detectable viral load1 by NASCOP region, Kenya AIDS Indicator Survey, 2012.
NASCOP region Overall Undetectable VL <550 copies/
uL
Detectable VL 550 copies/
uL
Region No. HIV Infected n wt2 % (95% CI3) n wt2 % (95% CI3) Ratio
National 617 235 38.8 (33.9–43.6) 382 61.2 (56.4–66.1) 1.6
Nairobi 63 26 43.8 (29.9–57.8) 37 56.2 (42.2–70.1) 1.28
Central 57 31 50.0 (34.7–65.3) 26 50.0 (34.7–65.3) 1.0
Coast 63 20 31.4 (16.2–46.6) 43 68.6 (53.4–83.8) 2.2
Eastern—North 28 13 50.4 (27.3–73.6) 15 49.6 (26.4–72.7) 0.98
Eastern—South 45 25 55.0 (38.8–71.2) 20 45.0 (28.8–61.2) 0.82
Nyanza 227 76 34.0 (27.3–40.6) 151 66.0 (59.4–72.7) 1.9
Rift Valley—North 36 10 27.9 (12.7–43.1) 26 72.1 (56.9–87.3) 2.7
Rift Valley—South 41 15 42.6 (19.2–66.1) 26 57.4 (33.9–80.8) 1.3
Western 57 19 34.0 (20.0–48.0) 38 66.0 (52.0–80.2) 1.9
NASCOP, National AIDS Control Programme. These regions correspond to former provinces of Kenya before the 2013 decentralization into counties.
1. Detectable viral load defined as HIV RNA concentration  550 copies/mL. Undetectable viral load defined as HIV RNA concentration < 550 copies/mL.
2. Weighted.
3. Confidence Interval.
doi:10.1371/journal.pone.0154318.t003
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prevalence of viremia at the county level where management of health programmes has
devolved in Kenya. Because our study relied on participant self-report, responses to sensitive
questions such as ART use and testing history may have been biased towards more socially
desirable answers, potentially leading to an under-representation of the true coverage of ART
use in the population and overestimation of suppression among untreated persons. We believe
that the addition of biological confirmation of ART to define “current ART use” in our analysis
helped to reduce this potential bias. Given the level of VL suppression found among persons
who were not on ART, our data support that VL suppression may not necessarily equal to
ART-related suppression. Only half of CD4+ T-cell count tests were available due to hemolysis
of specimens and hampered broader interpretation of viral suppression among those aware of
their HIV-infection.
Despite these limitations, the strength of our analysis is the nationally representative sample
that was used to expand our knowledge of population level coverage of HIV VL in Kenya. Fur-
thermore this is a benchmark for future trends in VL measurements among ART-naïve and
ART-experienced persons and will enable time-series analysis of VL and supplement HIV inci-
dence estimates in Kenya. We recommend that VL monitoring be an essential component of
national surveillance strategies, integrated in national monitoring and evaluation and health
information systems to monitor trends of infectivity at the population level.
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